Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: The case of Egypt

Clinical Infectious Diseases

Volumn 58, Issue 8, 2014, Pages 1064-1071

  Obach, Dorothée ^a,b   Deuffic Burban, Sylvie ^a,b,c   Esmat, Gamal ^d   Anwar, Wagida A ^e   Dewedar, Sahar ^e   Canva, Valérie ^f   Cousien, Anthony ^a   Doss, Wahid ^g   Mostafa, Aya ^e   Pol, Stanislas ^h,i   Buti, Maria ^j   Siebert, Uwe ^k,l   Fontanet, Arnaud ^m,n   Mohamed, Mostafa K ^e   Yazdanpanah, Yazdan ^a,o  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE LILLE   (France)

^d CAIRO UNIVERSITY   (Egypt)

^e AIN SHAMS UNIVERSITY   (Egypt)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^h Institut Cochin   (France)

ⁱ INSTITUT COCHIN   (France)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m INSTITUT PASTEUR   (France)

ⁿ University of Paris Cité   (France)

^o BICHAT HOSPITAL   (France)

more..

Author keywords

antiviral treatment; cost effectiveness; Egypt; HCV; resource limited countries

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EGYPT; FEMALE; GENOTYPE; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG THERAPY; ECONOMICS; HEALTH CARE COST; HEPATITIS C, CHRONIC; PATHOLOGY; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG THERAPY; EGYPT; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84897411263     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu066     Document Type: Article

References (33)

1. El-Zanaty F, Way A. Egypt demographic and health survey 2008. 2009. Available at: http://pdf.usaid.gov/pdf-docs/PNADO806.pdf. Accessed 4 June 2013.
2. Elkady A, Tanaka Y, Kurbanov F, et al. Genetic variability of hepatitis C virus in south Egypt and its possible clinical implication. J Med Virol 2009; 81:1015-23.
3. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355:887-91.
4. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
5. Ford N, Singh K, Cooke GS, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54:1465-72.
6. Mohamed MK, Bakr I, El-Hoseiny M, et al. HCV-related morbidity in a rural community of Egypt. J Med Virol 2006; 78:1185-9.
7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339-41.
8. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization, 2003. Available at: http://www.who.int/choice/publications/ p-2003-generalised-cea.pdf. Accessed 2 August 2013.
9. World Bank. World development indicators for Egypt. Available at: http://data.worldbank.org/country/egypt-arab-republic. Accessed 6 April 2013.
10. Vignier N, Esmat G, Sharkawy AE, et al. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. J Viral Hepat 2011; 18:e358-65.
11. El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009; 81:1576-83.
12. Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28:1112-9.
13. Schwarzinger M. Le décideur public face à la société en microéconomie de la santé? Faisabilité et implications des stratégies de valorisations en santé en France et en Egypte. Paris, France: Université Pierre et Marie Curie, 2008.
14. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-8.
15. Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009; 27:341-54.
16. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
17. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217-31.
18. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-21, 521.e1-6.
19. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-31.
20. United Nations Statistics. Demographic yearbook. Available at: http://unstats.un.org/unsd/demographic/products/dyb/dyb2009-2010.htm. Accessed 6 April 2013.
21. World Health Organization. Global Health Observatory Data Repository. Available at: http://apps.who.int/gho/data/node.main.687?lang=en. Accessed 14 January 2012.
22. Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa 2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b. AI444010 Study interim week 12 results. In: American Association for the Study of Liver Diseases, The Liver Meeting, San Francisco, CA, 2011.
23. Swan T. The hepatitis C treatment pipeline report. New York: Treatment Action Group, 2011. Available at: http://tagone.drupalgardens. com/sites/tagone.drupalgardens.com/files/HCV%20pipeline%202011. pdf. Accessed 4 June 2013.
24. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-8, 288.e1.
25. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-44.
26. Daltro-Oliveira R, Morais-de-Jesus M, Pettersen KM, Paraná R, Quarantini LC. Impact of sustained virologic response on quality of life in chronic HVC carriers. Ann Hepatol 2013; 12:399-407.
27. Amorim TGF, Staub GJ, Lazzarotto C, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol 2012; 11:855-61.
28. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-6.
30. Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One 2011; 6:e22309.
31. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54:1137-44.
32. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One 2012; 7:e34548.
33. Breban R, Arafa N, Leroy S, et al. Impact of mass antiviral treatment on HCV transmission in rural Egypt. In: European Association for the Study of the Liver, The International Liver Congress: Amsterdam, the Netherlands, 2013.